Efficacy and Safety of Brivudine in the Treatment of Herpes Zoster
ConditionHerpes Zoster
Trial statusRecruiting
Trial phasePhase 4
Trial typeInterventional
Biological sexAll
Age18+
SponsorPeking University Third Hospital
About this trial
This multicenter RCT aims to compare the efficacy and safety of Brivudine versus Famciclovir in treating acute herpes zoster. Primary objective: Evaluate pain reduction via Numeric Pain Rating Scale (NPRS) at Day 30. Secondary objectives: Compare NPRS at Day 3/Day 7/Day 14/Day 90, time to lesion resolution, Postherpetic Neuralgia (PHN) incidence, and safety.
Eligibility criteria
Qualifiers
Age ≥18 years, regardless of gender;
Signed Informed Consent Form;
Barrier methods: Condom or barrier cap (diaphragm or cervical cap);
Intrauterine device (IUD) or intrauterine system (IUS);
Disqualifiers
Allergy to brivudine, famciclovir, or penciclovir;
Current use of fluorouracil agents (e.g., 5-fluorouracil, capecitabine, tegafur, flucytosine);
Cancer patients currently undergoing chemotherapy;
Pregnant or lactating women;
Trial design
Treatments tested in this trial
- Brivudine
- Famciclovir
Treatment groups
140 Participants
are divided into 2 treatment groupsSponsors and collaborators
Peking University Third Hospital
Lead sponsor
Peking University First Hospital
Collaborator
Air Force Military Medical University, China
Collaborator
Beijing Hospital of Traditional Chinese Medicine
Collaborator
Xuanwu Hospital, Beijing
Collaborator
Source ClinicalTrials.gov